June is Men's Mental Health Awareness Month
AUGUSTA, Ga. (WJBF) – June is Men's Mental Health Awareness Month. I spoke to people who have seen boys and men silently struggle. When people think of depression, they typically think of sadness, specific language, or isolation, but in boys and men, it could look different. 'They may be more irritated. They may show a lot of aggression, a lot of anger, and so forth,' said Dominique Bond, School Counselor. 'So, these are some things that we can look for as well to really that can be some warning signs.' Marci Tankersley lost her brother to suicide. She tells me she never saw signs of him struggling with his mental health. 'The suicide rate in men is way higher than women, and I think that's why because they were never taught to express their emotions,' said Marci Tankersley, Mental Health Advocate. 'So that's the way my brother was raised. That's the way I mean so many men were raised, and my brother committed suicide when he was 21 years old. So, I don't remember him talking about anything. I didn't think he was depressed. But I do know now that he was, and he was silently struggling.' Mental health experts say the stigma that men can't show emotion makes it hard for them to express their feelings. 'Men need to really challenge their understanding of masculinity, and one of our understands of masculinity, which is very outdated, is that we are strong. We got it ourselves; we just got to tough it out, but in reality, we just have to address it,' said Bond. The American Foundation for Suicide Prevention aims to raise awareness through its 'Out of the Darkness' Walk in October. If you are struggling with mental health, you can also call the Suicide Hotline at 9-8-8.
'That tragedy and loss affects so many people down the line, The parents, the siblings. I just it can be, we can turn this thing around,' said Tankersley.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Bankers, athletes, students are using drugs. This hotline tries to keep them safe
There's a national overdose hotline that some Canadians call before they're about to use drugs. But the people dialling in aren't who you might think. Since the National Overdose Response Service (NORS) launched nearly five years ago, it's been reaching drug users who wouldn't typically use consumption and treatment sites. Shame and stigma can force people to use drugs alone, putting them at a greater risk of dying from an overdose. "We do know that a lot of people are hidden substance users," said Monty Ghosh, an addictions physician in Alberta and a NORS researcher. "It could be that they're afraid of losing their job, they're afraid that the family might leave them, they're afraid that the children might get taken away from them." Ghosh says that's where the hotline comes in. He says many people calling in have voluntarily disclosed that they have jobs and stable housing. "We're talking [about] people who are lawyers, physicians, engineers, people who are professional athletes," he said. "A lot of them are using the service because they don't identify as the same population as who uses a physical supervised consumption site." NORS is like a buddy system — operators stay on the line as people use drugs, ready to alert emergency services if they suspect the person has overdosed. People can also text the line, if they can't or don't want to call. To see who is reaching out and how the hotline works, CBC News met up with an operator in Hamilton, Ont., and listened in on multiple calls. WATCH | NORS operator provides advice while callers take drugs: The operator, Jodi, starts any call by confirming the person's address, telling them to keep their doors unlocked and pets away. These are all precautions in case EMS has to respond. One of the calls was from a student who was about to use crack. "I heard that there was a bad batch going around in my area and I was just wondering if you knew anything about it?" the person asked Jodi. LISTEN | Caller worries about 'bad batch' of drugs in area: A quick online search for alerts about tainted substances in the caller's region turned up empty, so Jodi cautioned, "Start low, go slow." Another caller, who was smoking fentanyl, told Jodi she's trying to use less frequently. When she does, she's started testing her drugs to stay safe. "Keep doing that," Jodi told her. "Just the stuff that's going around right now, it's actually really scary." LISTEN | Caller smokes fentanyl on the line: Once people use, Jodi stays on the line with them for about 10 to 15 minutes. She makes small talk — asking what they ate for dinner and what their plans are for the evening — all the while paying attention to how they're responding. "We're not therapists, we're not counsellors, we're not social workers," Jodi told CBC News. "We're not here to dig deep [into] why they started using drugs. It's just, 'Hey, how's it going today?'" No one overdosed the night CBC was on the line with Jodi, but it has happened. Of the almost 20,000 calls NORS has received, it's responded to more than 200 overdoses. According to the organization, nobody has died while using the line. In comparison, between March 2020 and February 2025, drug consumption and treatment sites across Canada received more than three million visits. "Our mandate at NORS is to keep people alive while they're using substances," said Lisa Morris-Miller, the executive director of the hotline. Her sister, Rebecca Morris-Miller, founded the line in December 2020, with the help of her friend Kim Ritchie. The pair had complicated pasts with drug use and met during a recovery program. With a cellphone, $1,000 and some volunteers, Ritchie says they started an early version of the hotline. By the end of 2020, she says partnerships with the University of Alberta and Health Canada led to funding that launched the line across the country. NORS is the first and only national overdose response hotline in Canada. For two years, Rebecca helped grow the service and became an advocate for people who were struggling. But throughout, she continued to struggle with her own addiction to fentanyl. In October 2022, Rebecca used drugs alone and didn't call her own hotline — and ended up dying from an overdose. "My opinion … is that there is still so much stigma associated with substance use, so much that … one of the key founders of this organization wouldn't call her own line," said Lisa Morris-Miller. Most NORS callers are from Ontario, Alberta, B.C. and Saskatchewan, according to researcher Ghosh. The most recent data from the hotline shows that of more than 3,200 calls, about 50 per cent were women and 16 per cent identified as gender diverse. In interviews, Ghosh said these callers told them that they prefer the hotline because of stigma and safety. While the organization hasn't released research on this, Ghosh says about 10 per cent of their calls have asked about referrals for mental health, opioid treatments or treatment centres. Ian Tait, communications director for the Ambulance Paramedics of British Columbia CUPE 873, says he isn't surprised to hear who is using the service. "In British Columbia … we go to million-dollar mansions for, you know, issues with substance use," said Tait, who is also an advanced care paramedic supervisor. He said that most of the overdose calls they respond to are for people who are unhoused, with mental health and substance use issues. Tait cited an app called Lifeguard, which he says people in B.C. will often use. Those with the app will activate it before taking their drug of choice and they then have to deactivate it within a certain period of time. If they don't, EMS will be alerted. "In this type of crisis, we have to look at ideas that are outside of the box," he said. Faith O'Toole, a 22-year-old Ottawa resident, has been revived multiple times because of the hotline. Having used crack and fentanyl since she was a teenager, O'Toole has lost count of how often she's overdosed. Her mom, Tamara, allowed Faith to keep living at home and using drugs, but insisted she call the hotline. "Of course I don't want my child to use drugs — nobody does. But if they're going to and I can't make her stop, what can I do to help keep her as safe as possible?" said Tamara. She estimates Faith has overdosed at least three times while using NORS. "Overdosing sucks, but the hotline is really useful," said Faith. "It's convenient. I mean, if you have a phone … you can call and you're safe." But Faith no longer lives at home and says she doesn't call the hotline as often. Despite how helpful virtual resources like hotlines and apps can be in this crisis, experts say they can't replace controversial drug consumption and treatment sites. The hotline fills some gaps — like being available around the clock and allowing people to smoke their drugs (which many drug sites don't allow) — but it's not accessible to everyone. For example, some people might not have a cellphone, says Caleb Clay, administrative manager for a mobile overdose prevention site at Sunshine House in Winnipeg. "I think that physical and virtual options can work hand in hand," he said. "I don't think physical sites will ever go away." Ghosh says these sites are essential, specifically because they're often used by people who are experiencing homelessness, and can provide them with a range of support. For example, they connect people to the local mental health care system, help bandage wounds or offer drug test strips and clean needles. But drug consumption sites have historically faced a lot of backlash. Most recently in Ontario, the provincial government shut down several facilities under new legislation and said it doesn't plan on approving any more sites. Right now, NORS has 20 employees across the country and is fully funded by Health Canada until 2028. NORS operator Jodi says people who call in just want to protect themselves, without judgment. She gets it, because she was once addicted to drugs, too. "It's kind of embarrassing," one caller told Jodi the evening CBC listened in. "What's embarrassing?" Jodi asked. "You know — you don't want to tell your family, but you don't want to be alone," they said. "Well, we're always frickin' here for you," Jodi said. "Nothing to be embarrassed [about] here."
Business Upturn
11 hours ago
- Business Upturn
Pliant Therapeutics Provides Update on BEACON-IPF
Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF). BEACON-IPF Trial Update BEACON-IPF was a randomized, double-blind, placebo-controlled, global Phase 2b/3 clinical trial evaluating patients with IPF. In March of this year, Pliant announced the voluntary discontinuation of BEACON-IPF following a prespecified data review and recommendation by the trial's independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, citing an imbalance in IPF-related adverse events. Following an analysis of the full safety and efficacy data from the BEACON-IPF trial, the Company is discontinuing development of bexotegrast in IPF. Results showed that at doses of 160 mg and 320 mg, bexotegrast demonstrated an unfavorable risk-benefit profile. Compared to placebo, bexotegrast-treated participants showed an increased risk of experiencing adverse events associated with IPF disease progression, defined as events of worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality. The average time to disease progression for bexotegrast-treated participants was 33 weeks, suggesting that the safety risk may not be apparent with shorter dosing duration as was the case in the prior INTEGRIS-IPF Phase 2a trial. At Week 12, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in forced vital capacity (FVC) decline of 72 mL (p<0.05) and 46 mL (p>0.05), respectively, compared to placebo. At Week 24, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in FVC decline of 58 mL (p>0.05) and 8 mL (p>0.05), respectively, compared to placebo. The full results from BEACON-IPF will be submitted for future publication. 'Although the decision to discontinue bexotegrast in IPF is disappointing for us and the many patients in need of new treatment options, we believe it is the right decision to protect patient safety,' said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. 'We sincerely thank all patients, their caregivers, the study investigators and their research teams who were part of the BEACON-IPF clinical program for their extensive efforts.' Oncology Phase 1 Enrollment Continues PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, designed to block TGF-β activation in the tumor microenvironment. PLN-101095 is currently undergoing a Phase 1 open-label trial as monotherapy and in combination with pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. In March, the Company announced interim results from this trial showing that PLN-101095 was generally well tolerated with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types. The trial is currently enrolling the fifth of five planned dose cohorts. Early Programs Supported by Proprietary Platform The Company's drug discovery platform consists of a proprietary library of over 15,000 integrin binding molecules, a comprehensive screening assay system (binding, integrin confirmation, ligand-induced internalization) and an advanced live human tissue program. The Company believes in the broad applicability of the platform across multiple disease areas including delivery of drug payloads to cells utilizing integrin receptor-binding molecules as tissue-specific delivery and internalization mechanisms. About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of integrin-based therapeutics. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of α v ß 8 and α v ß 1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α 7 β 1 targeting muscular dystrophies. Pliant's early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: Follow us on social media X, LinkedIn and Facebook. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'will,' 'expect,' 'anticipate,' 'estimate,' 'intend,' and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding development plans for PLN-101095, PLN-101325 and the Company's proprietary platform; and the Company's efforts to align its workforce and operations for its next steps. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of current macroeconomic, geopolitical and marketplace conditions on our business, operations, clinical supply and plans, our reliance on single-source third parties located in foreign jurisdictions, including China, for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, including the availability of additional term loans under our loan facility, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our Quarterly Report on Form 10-Q for the period ended March 31, 2025 which are available on the SEC's website at Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. Investor and Media Contact: Christopher KeenanVice President, Investor Relations and Corporate CommunicationsPliant Therapeutics, Inc. [email protected]
Business Wire
13 hours ago
- Business Wire
Align Technology Connects With Over 2,000 Doctors and Practice Staff at the 2025 Invisalign ® Asia Pacific (APAC) Summit
BANGKOK--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from the 2025 Invisalign ® Asia Pacific ('APAC') Summit held in Bangkok, Thailand, June 5 – 7, 2025. 'With more than 3 million Invisalign smiles across Asia Pacific, we know that this region sees some of the toughest clinical challenges in the field of dentistry,' said David Carr, Align executive vice president and managing director, APAC. 'The 2025 Invisalign Asia Pacific Summit underscores the importance of continued innovation and education. We are committed to working in partnership with doctors across the region in developing Invisalign treatment protocols that can help them transform smiles and change lives for even more patients.' Over three days, more than 2,000 doctors, practice team members, partners, and Align staff from across the region came together to explore the latest innovations in digital orthodontics and restorative dentistry. The summit featured over 60 expert speakers and more than 50 immersive breakout lectures and hands-on workshops, all designed to help doctors elevate clinical outcomes, streamline workflows, and grow their practices. Key topics covered include kids and teen, complex treatments, comprehensive dentistry and practice growth. 'This meeting provided us with a platform to connect with doctors across the full Asia Pacific region, encourage ongoing learning and sharing and showcase how our global innovations can support doctors in this market,' said Gigi Tsui, Align senior director, clinical, APAC. 'As we celebrate 20 million Invisalign smiles globally, including 3 million Invisalign smiles across the Asia Pacific region, it's critical that we continue to engage doctors for feedback and insights. This is fundamental to developing new innovations that meet the unique needs of doctors and patients across this region.' Attendees explored new developments across multiple interactive zones in the Innovation Hub, including: Kids and Teens: Featuring Invisalign First™, Invisalign® Palatal Expander System, and Invisalign® System with mandibular advancement featuring occlusal blocks ('MAOB'). ClinCheck® signature experience: Highlighting the 1-page Rx form (Flex Rx), preference templates, and ClinCheck ® Live Update. Comprehensive Dentistry: Showcasing iTero Lumina™ Pro dental imaging system, iTero™ intraoral scanner, Invisalign Smile Architect™, and Invisalign® Smile Video. Consumer & Branding: Demonstrating branding and tools to help doctors raise awareness of digital treatment options among patients of all ages. Clinical Excellence: Sharing clinical tools, evidence-based resources, education and insights available to doctors and staff. The summit also featured a Women Leadership session and provider recognition and lifetime achievement awardees. In addition to the core Asia Pacific Invisalign Summit, over 300 delegates across 78 universities also attended the Align APAC University Forum hosted at the renowned Chulalongkorn University in Bangkok. The forum served as a dynamic platform for cross-border collaboration and meaningful dialogue on how Align's evidence-based approach and cutting-edge innovations complements academic excellence and clinical training. Key highlights included keynote presentations by industry experts, interactive case-based discussions, resident showcases, and panels on integrating aligner therapy into university curriculum. The event also celebrated academic excellence with the APAC Case Challenge and Align research awards for APAC, while fostering peer-to-peer collaboration and inspiring the next generation of orthodontic leaders. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
